The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. (Q53262617)

12 May 2018

title

The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. (English)

1 reference

12 May 2018

0 references

1 reference

4

1 reference

12 May 2018

Jonatan Ising Bagger

object named as

Jonatan I Bagger

series ordinal

3

0 references

Asger Lund

object named as

Asger Lund

series ordinal

1

0 references

Tina Vilsbøll

series ordinal

2

object named as

Tina Vilsbøll

1 reference

12 May 2018

5

Filip K Knop

1 reference

12 May 2018

publication date

8 March 2011

1 reference

12 May 2018

American Journal of Physiology - Endocrinology and Metabolism

published in

1 reference

12 May 2018

volume

300

1 reference

12 May 2018

issue

6

1 reference

12 May 2018

page(s)

E1038-46

1 reference

12 May 2018

Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Abnormal glucagon response to arginine and its normalization in obese hyperinsulinaemic patients with glucose intolerance: importance of insulin action on pancreatic alpha cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

The Physiology of Glucagon-like Peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Regulation of alpha-cell function by the beta-cell in isolated human and rat islets deprived of glucose: the "switch-off" hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Insulin inhibits glucagon secretion by the activation of PI3-kinase in In-R1-G9 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

The analysis of repeated measures designs: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Validation of methods for measurement of insulin secretion in humans in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Quantification of beta-cell function during IVGTT in Type II and non-diabetic subjects: assessment of insulin secretion by mathematical methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Abnormal response of pancreatic glucagon to glycemic changes in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Glucose stimulates glucagon release in single rat alpha-cells by mechanisms that mirror the stimulus-secretion coupling in beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Glucose or insulin, but not zinc ions, inhibit glucagon secretion from mouse pancreatic alpha-cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Gut hypertrophy after gastric bypass is associated with increased glucagon-like peptide 2 and intestinal crypt cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Glucose inhibits glucagon secretion by a direct effect on mouse pancreatic alpha cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Reduced Incretin Effect in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Diminished Immunoreactive Gastric Inhibitory Polypeptide Response to a Meal in Newly Diagnosed Type I (Insulin-Dependent) Diabetics*

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00665.2010

10.1152/AJPENDO.00665.2010

21 January 2018

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/u2ld7benxzbw5pvdymayqosbge

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_u2ld7benxzbw5pvdymayqosbge

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/u2ld7benxzbw5pvdymayqosbge

mapped directly with Wikidata item

30 July 2022

based on heuristic

1 reference

https://api.fatcat.wiki/v0/release/u2ld7benxzbw5pvdymayqosbge